Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Marwa M Fouad, MD
- Phone Number: 01004531905
- Email: marwa.fouad@kasralainy.edu.eg
Study Contact Backup
- Name: Mohammed Elbatanouny, MD
- Phone Number: 01222174324
- Email: elbatanounym@yahoo.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male patients aged ≥ 18 years old
- Patients who fulfilled investigations according the study protocol.
- Patients who kept on follow up for the entire study.
- All patients fulfilling the clinical and radiological criteria of asbestosis (Existence of asbestos-specific pleural changes in high resolution computed topography HRCT (pleural plaques), Reticular changes in HRCT and restrictive lung function pattern, History of asbestos exposure, Absence of an alternative explanation for fibrotic lung disease )
- Clinically stable patients.
- Patients who signed informed consent
- Patients with mild-to-moderate IPF [forced vita capacity (FVC) ≥50% of predicted and diffusion capacity of carbon monoxide (DLCO) ≥30% of predicted].
- Duration since diagnosis (at least one year before the study)
Exclusion Criteria:
- Patients with peptic ulcer,
- Severe hepatic disease, hepatitis C infection or any of the following liver function test criteria above specified limits: aspartate or alanine aminotransferase (AST or ALT) >2.5 u above upper limit of normal level.
- Severe kidney disease, Cardiac disease, and Patients with other chronic pulmonary diseases, lung cancer
- Presence of coexisting respiratory infection
- History of alcohol or drugs abuse
- Patients with neuromuscular disease,
- Chronic renal failure,
- Patient on oxygen therapy,
- Life expectancy less than 6 months,
- History of malignancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Pirfinedone group
asbestosis patients given pirfenidone drug
|
drug intake three times daily for one year
Other Names:
|
|
No Intervention: Conventional group
Asbestosis patients on conventional treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ventilatory function change
Time Frame: after 6 months and 12 months from the start of the trial
|
Absolute change in percent predicted forced vital capacity
|
after 6 months and 12 months from the start of the trial
|
|
Diffusion test
Time Frame: after 6 months and 12 months from the start of the trial
|
Diffusion test change from baseline
|
after 6 months and 12 months from the start of the trial
|
|
radiological findings change
Time Frame: after 6 months and 12 months from the start of the trial
|
radiological changes in High resolution computed topography.
|
after 6 months and 12 months from the start of the trial
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marwa M Fouad, MD, Cairo University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Occupational Diseases
- Pneumoconiosis
- Lung Diseases, Interstitial
- Lung Injury
- Asbestosis
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Pirfenidone
Other Study ID Numbers
Other Study ID Numbers
- Pirfenidone in asbestosis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.